xenical for weight loss

xenical for weight loss

Home Alli-instructions for use, price, reviews
Required for Alli instruction and feedback? Information you can find on this page.

Producers: KRKA-RUS
Active substances

Class of diseases

Clinico-pharmacological group
Not specified. Cm. instruction
Pharmacological actions
Inhibiting gastrointestinal lipase

Pharmacotherapeutic group
Other hypolipidemic drugs
Table of contents

Indications for use of the preparation Alli
Release form of the drug Alli
The use of Alli during pregnancy

xenical for weight loss

Side effects
Dosage and administration
Interaction with other drugs
Cautions when receiving
Storage conditions
Shelf life
Indications for use of the preparation Alli

Long-term treatment of patients with conditions such as:

obesity (body mass index (BMI)? 30 kg/m2);

overweight (BMI? 28 kg/m2), including the presence of associated with obesity risk factors, coupled with a moderately low-calorie diet.

Alli you can assign in combination with hypoglycemic drugs and/or moderately low-calorie diet for patients with diabetes mellitus type 2 with overweight or obesity.
Release form of the drug Alli

capsules 120 mg; packing acejkovaa Pack 7 contour cardboard 3;

capsules 120 mg; packing acejkovaa Pack 7 contour cardboard 6;

capsules 120 mg; packing acejkovaa Pack 7 contour cardboard 12;

capsules 120 mg; contour 21 acejkovaa packaging cardboard bundle 1;

capsules 120 mg; contour 21 acejkovaa packaging cardboard bundle 2;

capsules 120 mg; contour 21 acejkovaa packaging cardboard bundle 4;

xenical for weight loss

The composition of the
Capsules 1 caps.
alli prefabricated granules 225.6 mg
(Orlistat-120 mg)
the composition of the semi-finished product-granules (100 g): orlistat-53.1915 g; AICC
excipients: ICC
capsules of gipromellozy
Shell composition capsules
Corps Capsule: hypromellose; water; titanium dioxide (E171)
kryshecka capsules: hypromellose; water; titanium dioxide (E171)
in a contour acheikova package 7 or 21 PCs.; in the paper cartons 3, 6 or 12 packs (7 capsules) or 1, 2 or 4 packaging (21 capsules).

Orlistat is a specific inhibitor of gastro-intestinal lipase, which has long-lasting effects. It has a therapeutic effect in the lumen of the stomach and small intestine, forming a covalent bond with an active serinovym plot of gastric and intestinal lipase. Inactivated enzyme thus loses the ability to break down dietary fats coming in the form of triglycerides, free fatty acids and-absorbable monohlycerides. Since the accumulation of triglycerides is not absorbed, calories in the body decreases, resulting in decreased body weight.

Therapeutic action of the preparation is done without suction system in the bloodstream. Orlistata activity leads to increased fat content in faecal masses after 24-48 h after administration of the drug. After preparation the fat content in faecal masses are usually returned to the original level via 48-72 h.

Suction. Orlistata absorption low. Via 8:00 after ingestion of the therapeutic dose orlistat unchanged in plasma is practically not defined (concentration 5 ng/ml). Signs of cumulation are absent, which confirms the minimal absorption of the drug.

cost of xenical

The distribution. In vitro orlistat for more than 99% is associated with plasma proteins (mostly with lipoproteins and albumin). In minimum quantities orlistat can penetrate the erythrocytes.

Metabolism. Orlistat is metabolized mainly in the wall of the bowel with the formation of pharmacologically active metabolites: M1 (gidrolizovannoe cetyrehclennoe laktonovoe ring) and M3 (M1 otseplennym N-formillejcinovym residue).

Excretion. The main route of elimination is through the intestine excretion is approximately 97% of the dose of the drug, of which 83%-orlistat in an unmodified form.

Cumulative excretion through the kidneys of all substances that are structurally related to orlistatom is less than 2% of the dose of the drug. Time for complete elimination is 3-5 days. Orlistat and metabolites can be displayed with jelchew.
The use of Alli during pregnancy

According to the results of preclinical studies: birth defects and embryo toxicity when taken orlistata were observed. Clinical data on the application of orlistata during pregnancy are not available, therefore, should not be prescribed orlistat at this time.

Data on the use of lactation are not available, therefore orlistat should not take during lactation.

hypersensitivity to orlistatu or any other component of the drug;

chronic malabsorption syndrome;




children up to age 18 years (safety and efficacy is not known). Side effects

Adverse reactions to orlistat basically marked by BLOOD and were caused by an increased amount of fat in the feces. Commonly observed side effects are mild and transitory nature. The appearance of those phenomena observed at the initial stage of treatment during the first 3 months (but no more than one occasion). Leaving the application orlistata the incidence of side effects is reduced.

Meet: flatulence, accompanied by secretions from the rectum, craving for defecation, greasy/oily stool, oily discharge from the rectum, liquid stool, upholstered Chair, the inclusion of fat in stool (steatorrhea), pain/discomfort in the abdomen, frequent urinating, pain/discomfort in the rectum, peremptory craving to defecation, incontinence, loss of teeth and gums; hypoglycemia in patients with type 2 diabetes, headache, anxiety, flu, tiredness, infections of the upper respiratory tract, urinary tract infections, dysmenorrhea, rarely: allergic reactions (e.g. itching, rash, urticaria, angioneuroticeski swelling, bronhospazm, anaphylaxis); very rarely diverticulitis, cholelithiasis, hepatitis (possibly severe), Bullous rashes, increased liver transaminaz and ALP.

Dosage and administration

Inside, squeezed water, immediately before each main meal, at the time of delivery or no later than one hour after eating.